Literature DB >> 8415613

Transgenic mouse model of malignant skin melanoma.

B Mintz1, W K Silvers.   

Abstract

Tyr-SV40E transgenic mice are specifically susceptible to melanoma due to expression of the oncogene in pigment cells. Mice of the more susceptible lines die young of early-onset eye melanomas, when skin melanomas are still infrequent and benign. To surmount this obstacle, skin from donors of two high-susceptibility lines was grafted to Tyr-SV40E hosts of a low-susceptibility line of the same inbred strain, thereby enabling the skin to outlive the donors and continue to grow in immunocompetent but tolerant hosts. Unexpectedly, donor pigment cells in all the grafts soon selectively proliferated close to areas of greatest wound healing, forming a dense black tracery, especially at the outer rim of the grafts. These lesions slowly grew radially within the grafts, producing irregular greyish patches. Local vertical thickenings then appeared and developed into small melanomas, which soon ulcerated through the epidermis. The tumors rapidly enlarged and became deeply invasive. Discrete black nevi also arose, with many becoming larger and distinctly blue, but those not near areas of pronounced wound healing did not progress to malignancy. In this first series, malignant melanoma resulted in all the grafts from the more susceptible of two donor lines and in some grafts from the other line. Distant metastases occurred in some cases from each line. Most tumors were hypomelanotic and heterogeneous, with lobes or areas differing in melanization. The results strongly suggest that growth factors and cytokines--known to be produced in wound repair--are triggering the growth and malignant conversion of these genetically susceptible melanocytes and that in the graft situation we are merely witnessing a caricature--a usefully exaggerated manifestation of the true events underlying the genesis of melanomas. The striking resemblance to the human malignancy, the genetic uniformity and different susceptibilities of the transgenic lines, and the experimental possibilities in the grafted mice all make them an excellent model of the disease.

Entities:  

Mesh:

Year:  1993        PMID: 8415613      PMCID: PMC47451          DOI: 10.1073/pnas.90.19.8817

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  34 in total

1.  Production of melanomas from DMBA-induced "blue nevi" in hairless mice with ultraviolet light.

Authors:  J H Epstein; W L Epstein; T Nakai
Journal:  J Natl Cancer Inst       Date:  1967-01       Impact factor: 13.506

2.  v-Ha-ras transgene abrogates the initiation step in mouse skin tumorigenesis: effects of phorbol esters and retinoic acid.

Authors:  A Leder; A Kuo; R D Cardiff; E Sinn; P Leder
Journal:  Proc Natl Acad Sci U S A       Date:  1990-12       Impact factor: 11.205

3.  Development of mammary hyperplasia and neoplasia in MMTV-TGF alpha transgenic mice.

Authors:  Y Matsui; S A Halter; J T Holt; B L Hogan; R J Coffey
Journal:  Cell       Date:  1990-06-15       Impact factor: 41.582

4.  Mediation of wound-related Rous sarcoma virus tumorigenesis by TGF-beta.

Authors:  M H Sieweke; N L Thompson; M B Sporn; M J Bissell
Journal:  Science       Date:  1990-06-29       Impact factor: 47.728

5.  TGF alpha overexpression in transgenic mice induces liver neoplasia and abnormal development of the mammary gland and pancreas.

Authors:  C Jhappan; C Stahle; R N Harkins; N Fausto; G H Smith; G T Merlino
Journal:  Cell       Date:  1990-06-15       Impact factor: 41.582

6.  Malignant melanoma in transgenic mice.

Authors:  M Bradl; A Klein-Szanto; S Porter; B Mintz
Journal:  Proc Natl Acad Sci U S A       Date:  1991-01-01       Impact factor: 11.205

7.  Malignancy of eye melanomas originating in the retinal pigment epithelium of transgenic mice after genetic ablation of choroidal melanocytes.

Authors:  B Mintz; A J Klein-Szanto
Journal:  Proc Natl Acad Sci U S A       Date:  1992-12-01       Impact factor: 11.205

Review 8.  Role of growth factors and their receptors in the development and progression of melanoma.

Authors:  I M Shih; M Herlyn
Journal:  J Invest Dermatol       Date:  1993-02       Impact factor: 8.551

9.  Assignment of a locus for familial melanoma, MLM, to chromosome 9p13-p22.

Authors:  L A Cannon-Albright; D E Goldgar; L J Meyer; C M Lewis; D E Anderson; J W Fountain; M E Hegi; R W Wiseman; E M Petty; A E Bale
Journal:  Science       Date:  1992-11-13       Impact factor: 47.728

10.  Ultraviolet radiation--induced malignant melanoma in Monodelphis domestica.

Authors:  R D Ley; L A Applegate; R S Padilla; T D Stuart
Journal:  Photochem Photobiol       Date:  1989-07       Impact factor: 3.421

View more
  17 in total

1.  Up-regulation of specific tyrosinase mRNAs in mouse melanomas with the c2j gene substituted for the wild-type tyrosinase allele: utilization in design of syngeneic immunotherapy models.

Authors:  N Le Fur; W K Silvers; S R Kelsall; B Mintz
Journal:  Proc Natl Acad Sci U S A       Date:  1997-07-08       Impact factor: 11.205

2.  Melanocyte transformation requires complete loss of all pocket protein function via a mechanism that mitigates the need for MAPK pathway activation.

Authors:  I D Tonks; P Mukhopadhyay; W A Schroder; A Sorolla; A W Mould; H Y Handoko; B Ferguson; H K Muller; P Keith; N K Hayward; G J Walker; G F Kay
Journal:  Oncogene       Date:  2017-02-13       Impact factor: 9.867

3.  Selective increase in specific alternative splice variants of tyrosinase in murine melanomas: a projected basis for immunotherapy.

Authors:  N Le Fur; S R Kelsall; W K Silvers; B Mintz
Journal:  Proc Natl Acad Sci U S A       Date:  1997-05-13       Impact factor: 11.205

4.  A synthetic peptide inhibitor for alpha-chemokines inhibits the growth of melanoma cell lines.

Authors:  S Hayashi; A Kurdowska; A B Cohen; M D Stevens; N Fujisawa; E J Miller
Journal:  J Clin Invest       Date:  1997-06-01       Impact factor: 14.808

Review 5.  Putting tumours in context.

Authors:  M J Bissell; D Radisky
Journal:  Nat Rev Cancer       Date:  2001-10       Impact factor: 60.716

6.  Changes in expression of putative antigens encoded by pigment genes in mouse melanomas at different stages of malignant progression.

Authors:  S J Orlow; V J Hearing; C Sakai; K Urabe; B K Zhou; W K Silvers; B Mintz
Journal:  Proc Natl Acad Sci U S A       Date:  1995-10-24       Impact factor: 11.205

7.  Development of a syngeneic mouse model of epithelial ovarian cancer.

Authors:  Bridget A Quinn; Fang Xiao; Laura Bickel; Lainie Martin; Xiang Hua; Andres Klein-Szanto; Denise C Connolly
Journal:  J Ovarian Res       Date:  2010-10-19       Impact factor: 4.234

8.  Do not scratch that mole!

Authors:  Mark Jelcic; Philipp Niethammer
Journal:  Trends Immunol       Date:  2015-08-04       Impact factor: 16.687

9.  Histopathogenesis of malignant skin melanoma induced in genetically susceptible transgenic mice.

Authors:  B Mintz; W K Silvers; A J Klein-Szanto
Journal:  Proc Natl Acad Sci U S A       Date:  1993-10-01       Impact factor: 11.205

Review 10.  Reconstructing skin cancers using animal models.

Authors:  Michael D Gober; Hasan M Bashir; John T Seykora
Journal:  Cancer Metastasis Rev       Date:  2013-06       Impact factor: 9.264

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.